GH Research PLC (GHRS)

Market Cap	537.16M
Revenue (ttm)	n/a
Net Income (ttm)	-38.96M
Shares Out	62.03M
EPS (ttm)	-0.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101,442
Open	8.88
Previous Close	9.10
Day's Range	8.22 - 8.80
52-Week Range	6.00 - 20.50
Beta	0.85
Analysts	Strong Buy
Price Target	30.86 (+256.35%)
Earnings Date	May 2, 2025

About GHRS

GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Employees: 50
• Stock Exchange: NASDAQ
• Ticker Symbol: GHRS
• Website: https://www.ghres.com

Analyst Forecast

According to 7 analysts, the average rating for GHRS stock is "Strong Buy." The 12-month stock price forecast is $30.86, which is an increase of 256.35% from the latest price.

Price Target

$30.86

(256.35% upside)

Analyst Consensus: Strong Buy